Abstract: The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Abstract: Various approaches to efficiently allocating and utilizing hardware resources in data centers while maintaining compliance with a service level objective (SLO) specified for a computational workload is translated into a hardware-level SLO to facilitate direct enforcement by the hardware processor, e.g., using a feedback control loop or model-based mapping of the hardware-level SLO to allocations of microarchitecture resources of the processor. In some embodiments, a computational model of the hardware behavior under resource contention is used to predict the application performance (e.g., as measured in terms of the hardware-level SLO) to be expected under certain contention scenarios. Scheduling of workloads among the compute nodes within the data center may be based on such predictions. In further embodiments, configurations of microservices are optimized to minimize hardware resources while meeting a specified performance goal.

Abstract: The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Abstract: A binding device for indicating the amount of negative pressure suction to use in a binding operation to treat hemorrhoids. The device is simple and convenient to use, and allows for more accurate binding operations. The binding device has a shell, a pushing pipe at the shell's front end, and a suction tube in the pushing pipe. A negative pressure device is in the shell. A scale cylinder has a cylinder body divided into two cavities and a piston piece within. The negative pressure device has a suction port in communication with the rear end of the suction tube and connected with one of the cylinder cavities. The cylinder body can move relative to the shell, and the shell has a scale part corresponding to that movement. The binding part is sleeved at the front end of the suction tube.

Abstract: The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Abstract: A robot system, including: a robot; a base supporting the robot; a controller connected to the robot; a processor connected to the controller; a depth camera connected to the processor; a flange plate; a coupling shaft including a first end and a second end; a mounting base including an elongated hole, a first side wall, and a second side wall; a sprayer including a mounting shaft; a first positioning bolt; a limit arm includes a first end and a second end; an axis pin; a limit shaft; a second positioning bolt; a gas cylinder; a piston rod; a connector; a shifter level; a trigger. The robot is connected to the first end of the coupling shaft via the flange plate. The second end of the coupling shaft is connected to the mounting base. The mounting shaft of the sprayer is disposed in the elongated hole of the mounting base.

Abstract: The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Abstract: Methods, apparatus, systems, and articles of manufacture for loading of a container image are disclosed. An example apparatus includes a prioritizer to determine a priority level at which a container is to be executed. A container controller is to determine a first expected location for a first set of layers of the container, the container controller to determine a second expected location for a second set of layers of the container, the first expected location and the second expected location determined based on the determined priority level, the second set of layers separated from the first set of layers in an image by a landmark. A container loader is to mount the first set of layers from the first expected location. A container executor is to initiate execution of the container based on the mounted first set of layers.

Abstract: A robot system, including: a robot; a base supporting the robot; a controller connected to the robot; a processor connected to the controller; a depth camera connected to the processor; a flange plate; a coupling shaft including a first end and a second end; a mounting base including an elongated hole, a first side wall, and a second side wall; a sprayer including a mounting shaft; a first positioning bolt; a limit arm includes a first end and a second end; an axis pin; a limit shaft; a second positioning bolt; a gas cylinder; a piston rod; a connector; a shifter level; a trigger. The robot is connected to the first end of the coupling shaft via the flange plate. The second end of the coupling shaft is connected to the mounting base. The mounting shaft of the sprayer is disposed in the elongated hole of the mounting base.

Abstract: The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.

Abstract: The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.